

Nuhad K Ibrahim

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1753863/nuhad-k-ibrahim-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

68

papers

3,435

citations

25

h-index

58

g-index

73

ext. papers

4,042

ext. citations

6.5

avg, IF

4.81

L-index

#	Paper	IF	Citations
68	Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. <i>Clinical Cancer Research</i> , 2002 , 8, 1038-44	12.9	428
67	A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. <i>Oncologist</i> , 2020 , 25, e936-e945	5.7	356
66	Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5983-92	2.2	345
65	Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6019-26	2.2	218
64	Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. <i>Oncologist</i> , 2011 , 16, 1092-100	5.7	181
63	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1081-1089	2.2	159
62	CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. <i>Nature Communications</i> , 2017 , 8, 15916	17.4	144
61	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2016 , 34, 945-52	2.2	121
60	Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. <i>Oncogene</i> , 1998 , 16, 2087-94	9.2	112
59	Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. <i>Lancet, The</i> , 2000 , 355, 281-3	40	100
58	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. <i>JAMA Oncology</i> , 2017 , 3, 509-515	13.4	97
57	Aromatase inhibitors in breast cancer: an overview. <i>Oncologist</i> , 2006 , 11, 553-62	5.7	94
56	Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. <i>Clinical Cancer Research</i> , 2002 , 8, 3407-18	12.9	91
55	CMET-09. PAN-CANCER PROFILES OF BRAIN METASTASES: PRIORITIZATION OF THERAPEUTIC TARGETS. <i>Neuro-Oncology</i> , 2017 , 19, vi40-vi41	1	78
54	Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial. <i>Journal of Cancer</i> , 2013 , 4, 577-84	4.5	63
53	Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2015 , 1, 1087-95	13.4	58
52	ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. <i>Clinical Cancer Research</i> , 2020 , 26, 2789-2799	12.9	57

51	Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. <i>Oncologist</i> , 2015 , 20, 466-73	5.7	54
50	Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 6822-30	12.9	54
49	Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 43, 471-8	3.5	45
48	Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 3996-4013	12.9	41
47	NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3006-3006	2.2	38
46	Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. <i>Cancer</i> , 1998 , 82, 965-9	6.4	37
45	Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. <i>Cancer</i> , 2004 , 101, 1508-13	6.4	32
44	Clinical development of the STn-KLH vaccine (Theratope). <i>Clinical Breast Cancer</i> , 2003 , 3 Suppl 4, S139-43		28
43	Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. <i>Cancer Immunology Research</i> , 2016 , 4, 755-65	12.5	25
42	Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2017 , 24, 2161-2167	3.1	24
41	Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. <i>British Journal of Cancer</i> , 2015 , 113, 1003-9	8.7	23
40	Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study. <i>Cancer</i> , 2017 , 123, 1115-1123	6.4	23
39	Therapeutic breast cancer vaccines: a new strategy for early-stage disease. <i>BioDrugs</i> , 2009 , 23, 277-87	7.9	21
38	Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. <i>Cancer</i> , 1999 , 86, 1251-7	6.4	20
37	Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT. <i>Cancer</i> , 2015 , 121, 3965-74	6.4	19
36	The evolving role of specific estrogen receptor modulators (SERMs). <i>Surgical Oncology</i> , 1999 , 8, 103-23	2.5	19
35	Developing anti-HER2 vaccines: Breast cancer experience. <i>International Journal of Cancer</i> , 2018 , 143, 2126-2132	7.5	17
34	Profiles of brain metastases: Prioritization of therapeutic targets. <i>International Journal of Cancer</i> , 2018 , 143, 3019-3026	7.5	17

33	Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2667-2675	2.2	16
32	A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. <i>British Journal of Cancer</i> , 2019 , 120, 1105-1112	8.7	15
31	Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2015 , 15, 325-31	3	15
30	Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 158, 67-77	4.4	14
29	Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy. <i>Breast Cancer Research</i> , 2018 , 20, 27	8.3	13
28	Radiologic findings in taxane induced colitis. <i>European Journal of Radiology</i> , 2008 , 66, 75-8	4.7	12
27	Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. <i>Cancer Investigation</i> , 2002 , 20, 29-37	2.1	12
26	Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. <i>Cancer Medicine</i> , 2020 , 9, 1025-1032	4.8	11
25	Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. <i>Journal of Cancer</i> , 2017 , 8, 2004-2009	4.5	9
24	Complete Metabolic Response on Interim F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. <i>Oncologist</i> , 2017 , 22, 526-534	5.7	8
23	Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. <i>Cancer</i> , 2001 , 91, 664-671	6.4	8
22	Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. <i>Cancer Investigation</i> , 2001 , 19, 459-66	2.1	7
21	Development of CNS metastases and survival in patients with inflammatory breast cancer. <i>Cancer</i> , 2018 , 124, 2299-2305	6.4	6
20	Evolution of Cancer Care in Response to the COVID-19 Pandemic. <i>Oncologist</i> , 2020 , 25, e1426-e1427	5.7	5
19	Ixabepilone development across the breast cancer continuum: a paradigm shift. <i>Cancer Management and Research</i> , 2010 , 2, 169-79	3.6	5
18	Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: MD Anderson Cancer Center experience. <i>International Journal of Cancer</i> , 2021 , 148, 961-970	7.5	5
17	MUC1 and Cancer Immunotherapy 2018 , 225-240		4
16	Phase II study of Ra-223 combined with hormonal therapy and denosumab for treatment of hormone receptor-positive breast cancer with bone-dominant metastasis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1065-1065	2.2	4

15	Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature. <i>Journal of Cancer</i> , 2014 , 5, 351-9	4.5	3
14	A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. <i>Scientific Reports</i> , 2021 , 11, 22242	4.9	3
13	Ixabepilone: Overview of Effectiveness, Safety, and Tolerability in Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 617874	5.3	3
12	CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel-How Far Science Has Come. <i>Clinical Cancer Research</i> , 2015 , 21, 1975-7	12.9	2
11	New antiestrogens in breast cancer: a review. <i>Breast Journal</i> , 1998 , 4, 213-29	1.2	2
10	Central nervous system miliary metastasis in breast cancer: a case series analysis and proposed identification criteria of a rare metastasis subtype. <i>British Journal of Cancer</i> , 2020 , 123, 1417-1423	8.7	2
9	Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving neoadjuvant therapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 572-572	2.2	1
8	Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases. <i>Npj Breast Cancer</i> , 2021 , 7, 28	7.8	1
7	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 1247-1255	12.9	1
6	A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. <i>Oncologist</i> , 2021 , 26, e230-e240 ¹	5.7	1
5	Molecular Spectra and Frequency Patterns of Somatic Mutations in Arab Women with Breast Cancer. <i>Oncologist</i> , 2021 , 26, e2086-e2089	5.7	1
4	Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer.. <i>Npj Breast Cancer</i> , 2022 , 8, 46	7.8	1
3	In Reply. <i>Oncologist</i> , 2020 , 25, e1252-e1253	5.7	
2	Reply to J. Wei et al. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101973	2.2	
1	RADI-17. Outcomes for patients with triple negative breast cancer treated with upfront stereotactic radiosurgery for brain metastases. <i>Neuro-Oncology Advances</i> , 2021 , 3, iii21-iii21	0.9	